secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001558370-24-000165
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus terminates TIGIT program collaboration with Junshi Biosciences after portfolio review
--------------------------------------------------------------------------------

- Delivered notice of termination on January 10, 2024 for the TIGIT Program (CHS-006).
- Decision follows Surface Oncology acquisition and portfolio prioritization; agreement remains effective for LOQTORZI (toripalimab-tpzi).
- Coherus will continue to support patients in ongoing CHS-006 studies (NCT05061628, NCT05757492).
- Company believes termination is in its best interests; wind-down expected over coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024000165/0001558370-24-000165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024000165/chrs-20240110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer